Small Pharma commences enrolling patients for its Phase IIa DMT-based clinical trial aimed at treating Major Depressive Disorder.

Field Trip is adding three new clinics to its network, with two of the three already open and the third opening imminently.

Compass Pathway’s fourth U.S. patent covers its Form A hydrate psilocybin, and is the first patent for this formulation.

Cash-rich psychedelic stocks are cheap. They are also building value for investors — at an accelerating rate.

The UK drug regulator (MHRS) has granted Small Pharma Fast-Track Designation with respect to SPL026 for Major Depressive Disorder (MDD).

Cybin has completed its 74th pre-clinical study and anticipates commencing human clinical studies in early 2022.

Small Pharma announces receiving DTC Eligibility and its OTCQB listing to broaden liquidity and increase access for U.S. investors.

Numinus prepares for a Phase I clinical trial of its proprietary psilocybin extract.

Oakland activists are hoping to expand upon the city’s current psychedelics decriminalization ordinance by creating a community-based model through which people could legally purchase entheogenic substances from local producers.

The New Mexico Finance Authority put forward a proposal that opens a $5 million line of credit for cannabis microbusinesses in order to promote social and economic fairness in the cannabis industry, the Associated Press reports.